keyword
MENU ▼
Read by QxMD icon Read
search

statin in acute coronary syndrome

keyword
https://www.readbyqxmd.com/read/29122809/eligibility-for-pcsk9-inhibitors-according-to-american-college-of-cardiology-acc-and-european-society-of-cardiology-european-atherosclerosis-society-esc-eas-guidelines-after-acute-coronary-syndromes
#1
Baris Gencer, Konstantinos C Koskinas, Lorenz Räber, Alexios Karagiannis, David Nanchen, Reto Auer, David Carballo, Sebastian Carballo, Roland Klingenberg, Dik Heg, Christian M Matter, Thomas F Lüscher, Nicolas Rodondi, François Mach, Stephan Windecker
BACKGROUND: The American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published recommendations for the use of proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors in situations of very high risk. We aim to assess in the real world the suitability of PCSK9 inhibitors for acute coronary syndromes. METHODS AND RESULTS: We analyzed a prospective Swiss cohort of 2023 patients hospitalized for acute coronary syndromes between 2009 and 2014 with available data for low-density lipoprotein cholesterol and lipid-lowering therapy at 1 year...
November 9, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29092845/clinical-predictors-for-lack-of-favorable-vascular-response-to-statin-therapy-in-patients-with-coronary-artery-disease-a-serial-optical-coherence-tomography-study
#2
Yoshiyasu Minami, Zhao Wang, Aaron D Aguirre, Daniel S Ong, Chong-Jin Kim, Shiro Uemura, Tsunenari Soeda, Hang Lee, James Fujimoto, Ik-Kyung Jang
BACKGROUND: Previous studies have demonstrated that statin therapy improves cardiac outcomes, probably by stabilizing thin-cap fibroatheroma in patients with coronary artery disease. However, major adverse cardiac events still occur in some patients, despite statin therapy. The aim of this study is to identify clinical predictors for the lack of a favorable vascular response to statin therapy in patients with coronary artery disease. METHODS AND RESULTS: A total of 140 nonculprit plaques from 84 patients with coronary artery disease who were treated with a statin and had serial optical coherence tomography imaging (median interval, 6...
November 1, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29071331/association-of-lipoprotein-a-with-risk-of-recurrent-ischemic-events-following-acute-coronary-syndrome-analysis-of-the-dal-outcomes-randomized-clinical-trial
#3
Gregory G Schwartz, Christie M Ballantyne, Philip J Barter, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Stephen J Nicholls, Anders G Olsson, Prediman K Shah, Jean-Claude Tardif, John Kittelson
Importance: It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS). Objective: To determine the association of Lp(a) concentration measured after ACS with the subsequent risk of ischemic cardiovascular events. Design, Setting, and Participants: This nested case-cohort analysis was performed as an ad hoc analysis of the dal-Outcomes randomized clinical trial...
October 25, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/29056945/comparison-of-the-low-density-lipoprotein-cholesterol-target-value-and-the-preventive-effect-of-statins-in-elderly-patients-and-younger-patients
#4
Akihiro Endo, Taiji Okada, Misun Pak, Yuzo Kagawa, Shimpei Ito, Hirotomo Sato, Kenji Kageshima, Yasuyuki Yoshida, Kazuaki Tanabe
OBJECTIVE: To assess whether the low-density lipoprotein cholesterol (LDL-C) target value and preventive effect of statins are different between elderly and younger patients. METHODS: We investigated 304 patients with previous percutaneous coronary intervention who underwent coronary angiography from January 2007 to December 2016 for examination of recurrent ischemia beyond the early restenosis. Patients were classified into two groups: age ≥ 75 years (elderly group: n = 140) and < 75 years (younger group: n = 164)...
June 2017: Journal of Geriatric Cardiology: JGC
https://www.readbyqxmd.com/read/29055633/colchicine-therapy-and-plaque-stabilization-in-patients-with-acute%C3%A2-coronary-syndrome-a-ct-coronary-angiography-study
#5
Kaivan Vaidya, Clare Arnott, Gonzalo J Martínez, Bernard Ng, Samuel McCormack, David R Sullivan, David S Celermajer, Sanjay Patel
OBJECTIVES: The authors sought to evaluate the plaque-modifying effects of low-dose colchicine therapy plus optimal medical therapy (OMT) in patients post-acute coronary syndrome (ACS), as assessed by coronary computed tomography angiography (coronary CTA). BACKGROUND: Colchicine therapy has been postulated to have beneficial anti-inflammatory effects in patients with ACS, translating into reduction in future adverse cardiovascular events. However, whether favorable plaque modification underpins this is yet unproven...
October 14, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29049325/effect-of-therapeutic-interchange-on-medication-reconciliation-during-hospitalization-and-upon-discharge-in-a-geriatric-population
#6
Jessica S Wang, Robert L Fogerty, Leora I Horwitz
BACKGROUND: Therapeutic interchange of a same class medication for an outpatient medication is a widespread practice during hospitalization in response to limited hospital formularies. However, therapeutic interchange may increase risk of medication errors. The objective was to characterize the prevalence and safety of therapeutic interchange. METHODS AND FINDINGS: Secondary analysis of a transitions of care study. We included patients over age 64 admitted to a tertiary care hospital between 2009-2010 with heart failure, pneumonia, or acute coronary syndrome who were taking a medication in any of six commonly-interchanged classes on admission: proton pump inhibitors (PPIs), histamine H2-receptor antagonists (H2 blockers), hydroxymethylglutaryl CoA reductase inhibitors (statins), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and inhaled corticosteroids (ICS)...
2017: PloS One
https://www.readbyqxmd.com/read/29040268/benefit-and-harm-of-intensive-blood-pressure-treatment-derivation-and-validation-of-risk-models-using-data-from-the-sprint-and-accord-trials
#7
Sanjay Basu, Jeremy B Sussman, Joseph Rigdon, Lauren Steimle, Brian T Denton, Rodney A Hayward
BACKGROUND: Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. We sought to develop and validate risk models for predicting absolute risk difference (increased risk or decreased risk) for CVD events and serious adverse events from intensive BP therapy. A secondary aim was to test if the statistical method of elastic net regularization would improve the estimation of risk models for predicting absolute risk difference, as compared to a traditional backwards variable selection approach...
October 2017: PLoS Medicine
https://www.readbyqxmd.com/read/29033508/predictors-of-mortality-in-elderly-patients-with-non-st-elevation-acute-coronary-syndrome-data-from-taiwan-acute-coronary-syndrome-full-spectrum-registry
#8
Cheng-Chun Wei, Shih-Huang Lee
BACKGROUND: Some difficulties and variations remain associated with the care of elderly patients with non-ST elevation acute coronary syndrome (NSTE-ACS). METHODS: We included 1470 patients from a Taiwan nationwide registry who fulfilled the criteria of NSTE-ACS, and stratified these patients by age and evaluated the treatment, complications and outcomes in different age groups. Furthermore, we analyzed risk factors and standards of care to determine the predictors of mortality...
July 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/29028484/cholesterol-target-value-attainment-and-lipid-lowering-therapy-in-patients-with-stable-or-acute-coronary-heart-disease-results-from-the-dyslipidemia-international-study-ii
#9
Anselm K Gitt, Dominik Lautsch, Jean Ferrières, Gaetano M De Ferrari, Ami Vyas, Carl A Baxter, Lori D Bash, Veronica Ashton, Martin Horack, Wael Almahmeed, Fu-Tien Chiang, Kian Keong Poh, Philippe Brudi, Baishali Ambegaonkar
BACKGROUND AND AIMS: Low-density lipoprotein cholesterol (LDL-C) is a major contributor to cardiovascular disease. In the Dyslipidemia International Study II (DYSIS II), we determined LDL-C target value attainment, use of lipid-lowering therapy (LLT), and cardiovascular outcomes in patients with stable coronary heart disease (CHD) and those suffering from an acute coronary syndrome (ACS). METHODS: DYSIS II included patients from 18 countries. Patients with either stable CHD or an ACS were enrolled if they were ≥18 years old and had a full lipid profile available...
November 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28992985/apoa1-and-apob-polymorphisms-and-apolipoprotein-concentrations-as-biomarkers-of-risk-in-acute-coronary-syndrome-relationship-with-lipid-lowering-therapy-effectiveness
#10
Fidel Casillas-Muñoz, Yeminia Valle, José Francisco Muñoz-Valle, Diana Emilia Martínez-Fernández, Gabriela Lizet Reynoso-Villalpando, Héctor Enrique Flores-Salinas, Mara Anaís Llamas-Covarrubias, Jorge Ramón Padilla-Gutiérrez
BACKGROUND AND OBJECTIVE: Lipid metabolism alterations contribute to acute coronary syndrome (ACS). rs670, rs5070 and rs693 polymorphisms have shown to modify the risk of cardiovascular disease. Apolipoprotein A-I (ApoA-I) plays a major role in reverse cholesterol transport; apolipoprotein B (ApoB) contributes to accumulation of cholesterol in the plaque. The aim of this study was to investigate the association of rs670 and rs5070 polymorphisms of APOA1 and rs693 polymorphism of APOB with ACS and circulating levels of its proteins and find if ApoB/ApoA-I could be implemented as an independent parameter of risk for cardiovascular disease and as a biomarker of lipid-lowering therapy effectiveness in Mexican population...
October 6, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28990943/-do-turkish-reimbursement-recommendations-cover-current-european-lipid-guidelines-a-retrospective-analysis-of-patients-presenting-with-first-acute-coronary-syndrom
#11
Deniz Demirci, Duygu Ersan Demirci, Murat Esin, Özkan Kayhan, Şakir Arslan
OBJECTIVE: This study was a comparison of the statin therapy protocol issued by the European Society of Cardiology (ESC) and the Ministry of Health's Health Implementation Directive (SUT) in Turkey, performed in order to assess the adequacy of hyperlipidemia treatment indications for primary prevention. METHODS: A total of 582 patients with first acute coronary syndrome were included in the study. Patients with noncritical stenosis observed on coronary angiography or a history of atherosclerotic disease were excluded...
October 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28982823/association-between-in-hospital-guideline-adherence-and-postdischarge-major-adverse-outcomes-of-patients-with-acute-coronary-syndrome-in-vietnam-a-prospective-cohort-study
#12
Thang Nguyen, Khanh K Le, Hoang T K Cao, Dao T T Tran, Linh M Ho, Trang N D Thai, Hoa T K Pham, Phong T Pham, Thao H Nguyen, Eelko Hak, Tam T Pham, Katja Taxis
OBJECTIVE: We aimed to determine the association between physician adherence to prescribing guideline-recommended medications during hospitalisation and 6-month major adverse outcomes of patients with acute coronary syndrome in Vietnam. DESIGN: Prospective cohort study. SETTING: The study was carried out in two public hospitals in Vietnam between January and October 2015. Patients were followed for 6 months after discharge. PARTICIPANTS: Patients who survived during hospitalisation with a discharge diagnosis of acute coronary syndrome and who were eligible for receiving at least one of the four guideline-recommended medications...
October 5, 2017: BMJ Open
https://www.readbyqxmd.com/read/28972004/prevention-of-stroke-with-the-addition-of-ezetimibe-to-statin-therapy-in-patients-with-acute-coronary-syndrome-in-improve-it
#13
Erin A Bohula, Stephen D Wiviott, Robert P Giugliano, Michael A Blazing, Jeong-Gun Park, Sabina A Murphy, Jennifer A White, Francois Mach, Frans J Van de Werf, Anthony J Dalby, Harvey D White, Andrew M Tershakovec, Christopher P Cannon, Eugene Braunwald
Background -Patients who experience an acute coronary syndrome (ACS) are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after ACS. We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT, with a focus on patients with a stroke prior to randomization. Methods -Post-ACS patients were randomized to placebo/simvastatin or ezetimibe/simvastatin and followed for a median of 6 years...
September 30, 2017: Circulation
https://www.readbyqxmd.com/read/28939569/recording-a-diagnosis-of-stroke-transient-ischaemic-attack-or-myocardial-infarction-in-primary-healthcare-and-the-association-with-dispensation-of-secondary-preventive-medication-a-registry-based-prospective-cohort-study
#14
Cecilia Dahlgren, Lukas Geary, Jan Hasselström, Clas Rehnberg, Karin Schenck-Gustafsson, Per Wändell, Mia von Euler
OBJECTIVES: The aim of this study was to explore whether recording in primary care of a previously recorded hospital diagnosis was associated with increased patient utilisation of recommended medications. DESIGN: Registry-based prospective cohort study. SETTING AND PARTICIPANTS: 19 072 patients with a hospital discharge diagnosis of transient ischaemic attack (TIA), stroke or acute coronary syndrome from hospitals in Stockholm County 2010-2013 were included in the study...
September 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/28935032/effect-of-definition-on-incidence-and-prognosis-of-type-2-myocardial-infarction
#15
MULTICENTER STUDY
Thomas Nestelberger, Jasper Boeddinghaus, Patrick Badertscher, Raphael Twerenbold, Karin Wildi, Dominik Breitenbücher, Zaid Sabti, Christian Puelacher, Maria Rubini Giménez, Nikola Kozhuharov, Ivo Strebel, Lorraine Sazgary, Deborah Schneider, Janina Jann, Jeanne du Fay de Lavallaz, Òscar Miró, F Javier Martin-Sanchez, Beata Morawiec, Damian Kawecki, Piotr Muzyk, Dagmar I Keller, Nicolas Geigy, Stefan Osswald, Tobias Reichlin, Christian Mueller
BACKGROUND: Uncertainties regarding the most appropriate definition and treatment of type 2 myocardial infarction (T2MI) due to supply-demand mismatch have contributed to inconsistent adoption in clinical practice. OBJECTIVES: This study sought a better understanding of the effect of the definition of T2MI on its incidence, treatment, and event-related mortality, thereby addressing an important unmet clinical need. METHODS: The final diagnosis was adjudicated in patients presenting with symptoms suggestive of myocardial infarction by 2 independent cardiologists by 2 methods: 1 method required the presence of coronary artery disease, a common interpretation of the 2007 universal definition (T2MI2007); and 1 method did not require coronary artery disease, the 2012 universal definition (T2MI2012)...
September 26, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28931790/clinical-characteristics-and-long-term-outcomes-of-rotational-atherectomy%C3%A3-j2t-multicenter-registry
#16
Iwao Okai, Tomotaka Dohi, Shinya Okazaki, Kentaro Jujo, Makoto Nakashima, Hisao Otsuki, Kazuki Tanaka, Hiroyuki Arashi, Ryuta Okabe, Fukuko Nagura, Yugo Nara, Hiroshi Tamura, Takeshi Kurata, Hideyuki Kawashima, Hiroyuki Kyono, Junichi Yamaguchi, Katsumi Miyauchi, Ken Kozuma, Nobuhisa Hagiwara, Hiroyuki Daida
BACKGROUND: Rotational atherectomy (RA) is an adjunct tool for the management of heavily calcified coronary lesions during percutaneous coronary intervention (PCI), but the long-term clinical outcomes of RA use remain unclear in this drug-eluting stent era.Methods and Results:This multi-center registry assessed the characteristics and outcomes of patients treated by RA for calcified coronary lesions between 2004 and 2015. Among 1,090 registered patients, mean age was 70±10 years and 815 (75%) were male...
September 21, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28917689/effect-of-early-pitavastatin-therapy-on-coronary-fibrous-cap-thickness-assessed-by-optical-coherence-tomography-in-patients-with-acute-coronary-syndrome-the-escort-study
#17
Tsuyoshi Nishiguchi, Takashi Kubo, Takashi Tanimoto, Yasushi Ino, Yoshiki Matsuo, Takashi Yamano, Kosei Terada, Hiroki Emori, Yosuke Katayama, Akira Taruya, Yuichi Ozaki, Yasutsugu Shiono, Kunihiro Shimamura, Takeyoshi Kameyama, Hironori Kitabata, Tomoyuki Yamaguchi, Atsushi Tanaka, Takeshi Hozumi, Takashi Akasaka
OBJECTIVES: The aim of the present study was to assess the effect of early statin therapy on fibrous-cap thickness in coronary plaques of patients with acute coronary syndrome (ACS) by using optical coherence tomography. BACKGROUND: Statins can contribute to the stabilization of coronary plaques. METHODS: This is a prospective, randomized, active-controlled, single-center study. Patients with ACS and untreated dyslipidemia were enrolled and randomly allocated (ratio 1:1) to either the early statin group (received pitavastatin 4 mg/day from baseline) or the late statin group (received pitavastatin 4 mg/day from 3 weeks after the baseline)...
September 9, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28916255/impact-of-nonfasting-triglycerides-high-density-lipoprotein-cholesterol-ratio-on-secondary-prevention-in-patients-treated-with-statins
#18
Ichiro Matsumoto, Atsushi Misaki, Mizuki Kurozumi, Tsunetatsu Nanba, Yuichiro Takagi
BACKGROUND: Some studies have demonstrated that low-density lipoprotein cholesterol (LDL-C) lowering therapy is one of the most important strategies to prevent coronary artery disease. Also, serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) are recognized as independent risk factors of cardiovascular diseases. The aim of this study was to investigate whether the nonfasting TG/HDL-C ratio could affect the incidence of cardiovascular events after percutaneous coronary intervention (PCI) even in patients treated with statins...
September 12, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28902639/the-role-of-specialized-prevention-clinics-for-the-short-term-follow-up-of-acute-coronary-syndromes
#19
Salih Kılıç, Evrim Şimşek, Hatice Soner Kemal, Elif İlkay Yüce, Cüneyt Türkoğlu, Meral Kayıkçıoğlu
OBJECTIVE: This study aimed to investigate the effect of specialized prevention clinics and standard clinics follow-ups on secondary protection after acute coronary syndrome (ACS) on cardiovascular risk factors. METHODS: A total of 118 patients who received thrombolytic therapy after being diagnosed with ST-segment elevation myocardial infarction were followed up for 6 months. After ACS, patients in a specialized prevention clinic (Group 1) (n=67) and those in a standard clinic (Group 2) (n=51) were compared in terms of the change in their lifestyle, management of risk factors, and drug compliance...
September 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28886926/2017-focused-update-of-the-2016%C3%A2-acc%C3%A2-expert-consensus-decision-pathway-on-the-role-of-non-statin-therapies-for-ldl-cholesterol-lowering-in%C3%A2-the-management-of-atherosclerotic-cardiovascular-disease-risk-a-report-of-the-american-college-of-cardiology-task-force
#20
Donald M Lloyd-Jones, Pamela B Morris, Christie M Ballantyne, Kim K Birtcher, David D Daly, Sondra M DePalma, Margo B Minissian, Carl E Orringer, Sidney C Smith
In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk. Since the publication of that document, additional evidence and perspectives have emerged from randomized clinical trials and other sources, particularly considering the longer-term efficacy and safety of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in secondary prevention of ASCVD...
October 3, 2017: Journal of the American College of Cardiology
keyword
keyword
45397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"